Actos Side Effects Linked to Risk of Bladder Cancer
Actos (generic pioglitazone hydrochloride) is an oral medication used for treatment of Type 2 diabetes. Recent research suggests that users may face an increased risk of bladder cancer from Actos the longer the medication is taken.
Possible signs or symptoms of bladder cancer that could be caused by side effects of Actos may include:
- Blood in the Urine
- Pain During Urination
- Frequent Urination
- Feeling of Need to Urinate Without Results
Financial compensation was obtained by former uses who pursued an Actos lawsuits after being diagnosed with bladder cancer from the type II diabetes drug. New cases are no longer being accepted. This page is maintained for informational purposes only.
ACTOS AND BLADDER CANCER
Actos is part of the same class of medications as Avandia (generic rosiglitazone), which has been linked to an increased risk of heart attacks, congestive heart failure and heart related death. Sales of Actos have increased significantly in recent years, due to potential concerns about side effects of Avandia. However, research suggests that Actos side effects are also a potential concern for diabetes patients.
Concerns about the potential risk of bladder cancer from Actos first surfaced when it was discovered that rats given the drug had a higher rate of bladder tumors. Recent results from an on-going 10 year study, involving nearly 200,000 patients with diabetes, suggests that there may be a risk of bladder cancer from Actos the longer the medication is taken.
The FDA announced in September 2010 that Takeda Pharmaceuticals, the manufacturer of Actos, provided interim data after five years that suggests there may be a risk of bladder cancer from Actos side effects the longer the medication is used. After 24 months, the rate of exposure and the increased Actos cancer risk reached statistical significance.
In June 2011, an Actos recall was issued in France after health authorities ordered doctors to stop prescribing the drug due to the possible risk of bladder cancer. A French study of public insurance data confirmed that there is a slight increase in the risk of bladder cancer with Actos use, adding to the prior concerns about long-term use of the medication.
Many have indicated that the FDA should remove Actos from the market in the United States as well, due to the risk of bladder cancer outweighing the potential benefits provided by the medication.
ATTORNEYS FOR ACTOS BLADDER CANCER SIDE EFFECTS
The attorneys at Saiontz & Kirk, P.A. previously evaluating potential Actos lawsuits for bladder cancer as a result of the manufacturers failure to adequately warn about the potential risk. All claims were reviewed by our Actos lawyers under a contingency fee retainer agreement, which means that there are no out of pocket expenses and no fees unless a recovery is obtained for an injury from Actos.
New Actos cases are no longer being accepted. This page is maintained for informational purposes only.